Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program-Reference-Cited by-同舟云学术

Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program

Published:2013-11-28 Issue:23 Volume:122 Page:3759-3766
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Ladetto Marco¹,Lobetti-Bodoni Chiara¹,Mantoan Barbara¹,Ceccarelli Manuela²,Boccomini Carola³,Genuardi Elisa¹,Chiappella Annalisa³,Baldini Luca⁴,Rossi Giuseppe⁵,Pulsoni Alessandro⁶,Di Raimondo Francesco⁷,Rigacci Luigi⁸,Pinto Antonello⁹,Galimberti Sara¹⁰,Bari Alessia¹¹,Rota-Scalabrini Delia¹²,Ferrari Angela¹³,Zaja Francesco¹⁴,Gallamini Andrea¹⁵,Specchia Giorgina¹⁶,Musto Pellegrino¹⁷,Rossi Francesca Gaia⁴,Gamba Enrica¹⁸,Evangelista Andrea²,Vitolo Umberto³

Affiliation:

1. Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Turin, Turin, Italy;

2. Unit of Cancer Epidemiology, Azienda Ospedaliera Città della Salute e della Scienza, Turin, Italy;

3. Division of Hematology 2, Azienda Ospedaliera Città della Salute e della Scienza, Turin, Italy;

4. Division of Hematology, Fondazione IRCCS Cà Granda OM Policlinico, University of Milan, Milan, Italy;

5. Division of Hematology, Spedali Civili Spedali Civili Hospital and University, Brescia, Italy;

6. Division of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy;

7. Division of Hematology, Oncology, and Clinical Pathology and Department of Clinical and Molecular Biomedicine, University of Catania, Catania, Italy;

8. Hematology Functional Unit, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy;

9. Istituto Nazionale Tumori, Fondazione “G. Pascale,” Istituto Di Ricovero e Cura a Carattere Scientifico, Naples, Italy;

10. Department of Oncology, Transplants and Advanced Technologies, Section of Haematology, Pisa University, Pisa, Italy;

11. Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy;

12. Universitary Division of Medical Oncology, “Fondazione del Piemonte per l’Oncologia-Istituto per la ricerca e la Cura del Cancro,” Candiolo, Turin, Italy;

13. Haematology Unit, Arcispedale Santa Maria Nuova, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia, Italy;

14. Division of Hematology and Bone Marrow Transplantation, Azienda Ospedaliero-Universitaria Udine, Udine, Italy;

15. Hematology Department and Bone Marrow Transplantation Unit, Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy;

16. Division of Hematology, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy;

17. Direzione Scientifica, Istituto di Ricovero e Cura a Carattere Scientifico Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy; and

18. Roche, S.p.A., Monza, Italy

Abstract

Key Points PCR negativity is a strong outcome predictor after rituximab-intensive immunochemotherapy at multiple posttreatment times. PCR is predictive even when maintenance is delivered, and accumulation of PCR-negative results further reduces the likelihood of relapse.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/122/23/3759/1464618/3759.pdf

Reference52 articles.

1. Follicular lymphoma: 2011 update on diagnosis and management.;Freedman;Am J Hematol,2011

2. New treatment options have changed the survival of patients with follicular lymphoma.;Fisher;J Clin Oncol,2005

3. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center.;Liu;J Clin Oncol,2006

4. All advanced stage non-Hodgkin’s lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment.;Gribben;Blood,1991

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial;The Lancet Haematology;2024-07

2. Defining an Optimized Workflow for Enriching and Analyzing Residual Tumor Populations Using Intracellular Markers;The Journal of Molecular Diagnostics;2024-04

3. Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study;Journal of Clinical Oncology;2023-12-14

4. Measurable Residual Disease Monitoring in Lymphoma;Current Hematologic Malignancy Reports;2023-11-06

5. Clinical applications of circulating tumor DNA in indolent B-cell lymphomas;Seminars in Hematology;2023-07